



Acute Myeloid Leukemia: Current Progress and Future Directions

Guest Editors:

Dr. Valeria Visconte

Department of Translational
Hematology and Oncology
Research, Taussig Cancer
Institute, Cleveland Clinic,
Cleveland, OH 44195, USA

Dr. Luca Guarnera

1. Department of Translational
Hematology & Oncology
Research, Taussig Cancer
Institute, Cleveland Clinic,
Cleveland, OH, USA
2. Department of Biomedicine
and Prevention, Tor Vergata
University, Rome, Italy

Deadline for manuscript
submissions:

30 March 2025

Message from the Guest Editors

Acute myeloid leukemia (AML) is an aggressive malignancy spanning heterogenous clinical and molecular phenotypes. In recent years, huge advances in our understanding of the disease's biology have led us to gain deeper insight into the genetic features and the bone marrow microenvironment changes underpinning the process of leukemogenesis, paving the way to targeted treatments. This Special Issue will focus on the recent advances concerning all facets of personalized AML management, including both treatment investigations and translational research, as well as the bench-side management of complications and all-day practice. Moreover, current and future risk disease stratifications, prognostic markers and models, and applications of novel techniques regarding the disease's multimodal nature will be considered. We will highly appreciate and welcome the submissions of original papers and reviews in line with the aim of this Special Issue.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)